Pulnovo Medical Names Dr. Francis Duhay as Global Chief Medical Officer
Pulnovo Medical has appointed Dr. Francis Duhay, MD, MBA, FACS as Global Chief Medical Officer. Dr. Duhay, a board-certified General and Cardiothoracic Surgeon, brings over 25 years of experience in clinical medicine, medical device innovation, and executive leadership.
As former Chief Medical Officer at Edwards Lifesciences (NYSE: EW), Dr. Duhay was instrumental in developing the TAVR program, which generates over $4.0 billion in annual revenue across 80+ countries. His experience includes leading 88 clinical studies and working with key regulatory bodies like FDA and CMS.
This appointment strengthens Pulnovo's global medical leadership as it advances its Pulmonary Artery Denervation (PADN) program and expands internationally.
Pulnovo Medical ha nominato Dr. Francis Duhay, MD, MBA, FACS come Chief Medical Officer Globale. Il Dr. Duhay, chirurgo generale e cardiotoracico certificato, vanta oltre 25 anni di esperienza in medicina clinica, innovazione nei dispositivi medici e ruoli dirigenziali.
In qualità di precedente Chief Medical Officer presso Edwards Lifesciences (NYSE: EW), il Dr. Duhay ha svolto un ruolo chiave nello sviluppo del programma TAVR, che genera oltre $4,0 miliardi di ricavi annui in più di 80 paesi. Ha diretto 88 studi clinici e ha collaborato con autorità regolatorie come FDA e CMS.
Questa nomina rafforza la leadership medica globale di Pulnovo mentre l'azienda porta avanti il suo programma di Denervazione dell'Arteria Polmonare (PADN) e amplia la propria presenza internazionale.
Pulnovo Medical ha nombrado a Dr. Francis Duhay, MD, MBA, FACS como Chief Medical Officer Global. El Dr. Duhay, cirujano general y cardiotorácico certificado, aporta más de 25 años de experiencia en medicina clínica, innovación en dispositivos médicos y liderazgo ejecutivo.
Como ex Chief Medical Officer en Edwards Lifesciences (NYSE: EW), el Dr. Duhay fue fundamental en el desarrollo del programa TAVR, que genera más de $4.0 mil millones en ingresos anuales en más de 80 países. Su trayectoria incluye la dirección de 88 estudios clínicos y la colaboración con organismos reguladores clave como la FDA y CMS.
Este nombramiento refuerza el liderazgo médico global de Pulnovo mientras avanza su programa de Denervación de la Arteria Pulmonar (PADN) y expande su presencia internacional.
Pulnovo Medical는 Dr. Francis Duhay, MD, MBA, FACS를 글로벌 최고 의료책임자(CMO)로 임명했습니다. 듀헤 박사는 일반외과 및 심장흉부외과 전문의로서 임상 의학, 의료기기 혁신 및 경영 리더십 분야에서 25년 이상의 경험을 보유하고 있습니다.
전 Edwards Lifesciences (NYSE: EW) 최고 의료책임자로서 듀헤 박사는 전세계 80개국 이상에서 연간 40억 달러 이상의 매출을 창출하는 TAVR 프로그램 개발에 핵심적 역할을 했습니다. 또한 88건의 임상 연구를 이끌었고 FDA 및 CMS 등 주요 규제 기관과 협력한 경험이 있습니다.
이번 임명은 Pulnovo가 폐동맥 신경차단(PADN) 프로그램을 진전시키고 국제적으로 확장하는 가운데 글로벌 의료 리더십을 강화합니다.
Pulnovo Medical a nommé Dr. Francis Duhay, MD, MBA, FACS au poste de Chief Medical Officer mondial. Le Dr Duhay, chirurgien général et cardio‑thoracique certifié, apporte plus de 25 ans d'expérience en médecine clinique, innovation dans les dispositifs médicaux et direction exécutive.
Ancien Chief Medical Officer chez Edwards Lifesciences (NYSE: EW), le Dr Duhay a joué un rôle déterminant dans le développement du programme TAVR, qui génère plus de 4,0 milliards de dollars de revenus annuels dans plus de 80 pays. Il a dirigé 88 études cliniques et travaillé avec des autorités réglementaires clés telles que la FDA et le CMS.
Cette nomination renforce le leadership médical mondial de Pulnovo alors que la société fait progresser son programme de dénervation de l'artère pulmonaire (PADN) et étend sa présence internationale.
Pulnovo Medical hat Dr. Francis Duhay, MD, MBA, FACS zum Global Chief Medical Officer ernannt. Dr. Duhay, ein fachlich zertifizierter Allgemein‑ und Herz-Thorax-Chirurg, bringt über 25 Jahre Erfahrung in klinischer Medizin, medizintechnischer Innovation und Führungsebene mit.
Als ehemaliger Chief Medical Officer bei Edwards Lifesciences (NYSE: EW) spielte Dr. Duhay eine entscheidende Rolle beim Aufbau des TAVR‑Programms, das in mehr als 80 Ländern über $4,0 Milliarden Jahresumsatz erzielt. Zu seinen Erfahrungen zählen die Leitung von 88 klinischen Studien sowie die Zusammenarbeit mit wichtigen Zulassungsbehörden wie der FDA und CMS.
Die Berufung stärkt Pulnovos weltweite medizinische Führungsposition, während das Unternehmen sein Programm zur Denervierung der Lungenarterie (PADN) vorantreibt und international expandiert.
- Appointment of highly experienced former Edwards Lifesciences CMO with 25+ years of expertise
- Dr. Duhay's proven track record in developing TAVR, a $4.0B revenue program
- Experience leading 88 clinical studies and working with major regulatory bodies
- Strategic strengthening of medical leadership for PADN program advancement
- None.
Dr. Duhay, a board-certified General and Cardiothoracic Surgeon, brings over 25 years of experience in clinical medicine, medical device innovation, and executive leadership. As former Chief Medical Officer at Edwards Lifesciences (NYSE: EW), he played a decisive role in the development, clinical validation, and worldwide adoption of Transcatheter Aortic Valve Replacement (TAVR)—a transformative therapy now recognized as one of the most successful cardiovascular procedures in the history of medical devices., with over
His career spans leadership of 88 clinical studies across multiple specialties and close collaboration with global regulatory bodies, including the
With Dr. Duhay's appointment, Pulnovo strengthens its global medical leadership as it advances its Pulmonary Artery Denervation (PADN) program and expands its footprint in international markets. His proven track record in bringing paradigm-shifting cardiovascular technologies from concept to global standard of care positions Pulnovo for its next phase of innovation and growth.
View original content:https://www.prnewswire.com/news-releases/pulnovo-medical-names-dr-francis-duhay-as-global-chief-medical-officer-302537529.html
SOURCE Pulnovo Medical
FAQ
Who is Dr. Francis Duhay and what is his new role at Pulnovo Medical?
What was Dr. Duhay's major achievement at Edwards Lifesciences (NYSE: EW)?
How many clinical studies has Dr. Francis Duhay led in his career?
What is Pulnovo Medical's key program that Dr. Duhay will oversee?
